|
Features
|
Training set TCGA RNA-seq cohort (n = 660)
|
Validation set CGGA RNA-seq cohort (n = 668)
|
|---|
|
NTRSLow(n = 391)
|
NTRSHigh(n = 269)
|
p-value
|
NTRSLow(n = 281)
|
NTRSHigh(n = 387)
|
p-value
|
|---|
|
Age
|
|
Mean (range)
|
41 (17–75)
|
56 (14–89)
|
< 0.001***
|
41 (12–69)
|
45 (11–76)
|
< 0.001***
|
|
Gender
|
|
Female
|
170
|
108
|
0.38
|
135
|
153
|
< 0.05*
|
|
Male
|
219
|
161
| |
146
|
234
| |
|
NA
|
2
|
0
| | | | |
|
WHO Grade
|
|
II
|
224
|
19
|
< 0.001***
|
106
|
74
|
< 0.001***
|
|
III
|
163
|
96
| |
136
|
115
| |
|
IV
|
3
|
154
| |
39
|
198
| |
|
NA
|
1
|
0
| | | | |
|
IDH status
|
|
Wildtype
|
12
|
221
|
< 0.001***
|
44
|
233
|
< 0.001***
|
|
Mutant
|
373
|
43
| |
228
|
115
| |
|
NA
|
6
|
5
| |
9
|
39
| |
|
Chr.1p/19q status
|
|
Noncodeletion
|
223
|
249
|
< 0.001***
|
162
|
299
|
< 0.001***
|
|
Codeletion
|
163
|
3
| |
117
|
24
| |
|
NA
|
5
|
17
| |
2
|
64
| |
|
Histology
|
|
Astrocytoma
|
120
|
71
|
< 0.001***
|
57
|
67
|
< 0.001***
|
|
Oligodendroglioma
|
168
|
17
| |
52
|
29
| |
|
Oligoastrocytoma
|
100
|
27
| |
133
|
93
| |
|
Glioblastoma
|
3
|
154
| |
39
|
198
| |
|
MGMT promoter status
|
|
Methylated
|
352
|
111
|
< 0.001***
|
/
|
/
| |
|
Unmethylated
|
30
|
123
| |
/
|
/
| |
|
NA
|
9
|
35
| |
/
|
/
| |
|
Chr.7.gain&Chr.10.loss
|
|
Yes
|
1
|
146
|
< 0.001***
|
/
|
/
| |
|
No
|
380
|
106
| |
/
|
/
| |
|
NA
|
10
|
17
| |
/
|
/
| |
|
Chr.19&20 gain
|
|
Non-gain
|
381
|
222
|
< 0.001***
|
/
|
/
| |
|
Gain
|
0
|
30
| |
/
|
/
| |
|
NA
|
10
|
17
| |
/
|
/
| |
|
ATRX status
|
|
Wildtype
|
227
|
218
|
< 0.001***
|
/
|
/
| |
|
Mutant
|
155
|
33
| |
/
|
/
| |
|
NA
|
9
|
18
| |
/
|
/
| |
- P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) is regarded as statistically significant
- NA not applicable
